Ergoteles’s ImmunityBio IBRX Stock Holding History

Ergoteles’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-135,300	Closed	-$503K	–	1725
2022 Q2	$503K	Buy	+135,300	New	+$543K	0.02%	837
2022 Q1	–	Sell	-17,264	Closed	-$105K	–	1407
2021 Q4	$105K	Buy	+17,264	New	+$130K	﹤0.01%	1148
2021 Q2	–	Sell	-19,200	Closed	-$456K	–	1580
2021 Q1	$456K	Buy	+19,200	New	+$498K	0.01%	501
2020 Q4	–	Sell	-16,374	Closed	-$114K	–	784
2020 Q3	$114K	Buy	+16,374	New	+$163K	0.02%	530

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ergoteles's IBRX Position: Q3 2022 in Review

Ergoteles sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 135,300 shares — an estimated $503K sold.

Ergoteles first reported a position in IBRX in Q3 2020 and held it in 4 quarters. The position peaked at $503K in Q2 2022. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

Ergoteles reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 135,300 ImmunityBio shares in Q3 2022, an estimated $503K.
Ergoteles first reported a position in ImmunityBio in Q3 2020 and held it in 4 quarters.
Ergoteles's ImmunityBio position peaked at $503K in Q2 2022.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.